AZULTIS
LIVE

Serial Number

97877494

Owner

PROVEPHARM LIFE SOLUTIONS

Attorney

Kaitlyn M. Garvin

Filing Date

Apr 7, 2023

Add to watchlist:

No watchlists yet
View on USPTO

AZULTIS Trademark

Serial Number: 97877494 • Registration: 7637834

AZULTIS is a trademark filed by PROVEPHARM LIFE SOLUTIONS on April 7, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

PROVEPHARM LIFE SOLUTIONS (19 trademarks)

22, RUE MARC DONADILLE
MARSEILLE 13013 , FR

Entity Type: 33

Trademark Details

Filing Date

April 7, 2023

Registration Date

January 7, 2025

Published for Opposition

September 17, 2024

Goods & Services

Pharmaceutical preparations for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urological systems by instillation, injection or local application; chemical preparations for medical use for marking tissue by injection in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable administration, for oral and topical antiseptic treatment, for marking and functional verification of gynecological and urological systems by instillation, injection or local application; injectable pharmaceutical solutions for use as a marker during gastrointestinal endoscopy; injectable pharmaceutical solutions used as a contrast solution for medical imaging procedures; injectable pharmaceutical solutions for medical diagnostic purposes for viewing and marking tissue; injectable pharmaceutical solutions used as an aid in visualization of topographic irregularities and in delineation of polypoid or flat lesions, including adenomas; injectable pharmaceutical solutions used for polyps or lesions resection medicines for tissue staining; injectable pharmaceutical solutions for use as a marker during visceral surgery; injectable pharmaceutical solutions for the detection of amniotic fluid leaks; injectable pharmaceutical solutions for use as a marker during cystoscopy and ureteral catheterization; injectable pharmaceutical solutions for use as a marker during vessel delineation and tumor localization procedures; clinical medical reagents; synthetic peptides for pharmaceutical use, namely, for cancer treatments, immunotherapy, cell therapy, antivirals and antibiotics; phytotherapy preparations for medical use; diagnostic preparations in vials for medical use; drug delivery agents in the form of injectable compounds being pharmaceutical solutions in pre-filled vials that facilitate the delivery of pharmaceutical preparations; pre-filled syringes for medical and clinical purposes, sold filled with injectable pharmaceutical solutions for marking tissue by injection application in surgery and internal medicine, for marking tissue of the digestive system by oral, anal or injectable, for the antiseptic treatment orally or topically, for marking and functional verification gynecological and urological systems, by instillation, injection or local application

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 7, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 7, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 17, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 17, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 28, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 12, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 11, 2024 CRFA
ASSIGNED TO LIE
Aug 10, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 23, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 16, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 16, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 16, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 4, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 2, 2023 NWOS
NEW APPLICATION ENTERED
Apr 11, 2023 NWAP